http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0622293-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e9ca0a0e17a79c02cd2949f5a76b092 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2006-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d4a502a304d2f8cc1f7b018afd1bf3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7c8b8488d732e8c5dd9561e72fe1637 |
| publicationDate | 2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0622293-A2 |
| titleOfInvention | use of metalloproteinase tissue inhibitor (typ) linked to glycosylphosphatidylinositol (gpi) fixations for cancer treatment |
| abstract | USE OF METALLOPROTEINASE TISSUE INHIBITOR (TIMP) CONNECTED TO GLYCOSYPHOSPHATIDYLINOSITOL (GPI) FIXATIONS FOR CANCER TREATMENT The present invention relates to tissue inhibitor fusion constructions fixed by glycosylphosphatidylinositol (GPI) and its metalloproteins (GPI) use of metalloproteins and metalloproteins. for the treatment of cancer and in regenerative medicine. Through this approach, GPI-fixed TIMP proteins are incorporated into the surface membrane of tumor cells and make tumor cells sensitive to FAS-induced apoptosis. In addition, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, TIMP is bound to mucin followed by GPI to increase the surface presentation. The use of GPI to bind TIMP makes the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer after an incomplete surgical resection of primary tumors in an individual. |
| priorityDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 764.